Iran Joins Group of 4 Countries in Producing “rTMS” Machine to Help Patients with Parkinson's Disease
Repetitive transcranial magnetic stimulation (rTMS) is a potent tool for modulating endogenous oscillations in humans. In repetitive transcranial magnetic stimulation (rTMS), an electromagnetic coil placed against the scalp creates a magnetic field that stimulates certain areas of the brain.
Each magnetic pulse easily and painlessly passes through the scalp and bones and membranes of the brain and reaches the neurons and causes the short-term activity of the neurons in that part of the brain.
In addition to being safe, the magnetic field created as a result of rTMS does not cause an unpleasant feeling in the person, and in contrast to the passage of the magnetic field through the brain, it creates a current in the nerve cells of the brain and stimulates these cells.
The rTMS can be performed for each patient specifically and in a specific area of the brain.
Iran used to import the device, but now a group of researchers at a technology company have managed to design and manufacture it inside the country.
Abbasi, one of the researchers that designed the rTMS, told Iranian media that their technological company under his management have been importing rTMS and FMS devices since 2010, adding, "But, we have now achieved the technical know-how of designing and manufacturing this device to make Iran the fourth country that has that knowledge to produce that machine."
“The rTMS (functional magnetic stimulation) machine is used in the field of neurology to treat patients with depression, migraine and improve the movement in patients that have experienced a stroke. This device is also used for the rehabilitation of people with Parkinson's disease,” he explained.
Abbasi said that producing the rFMS is another technological achievement of their company, adding, "The function of this device is similar to that of the rTMS device, with the difference that the FMS covers more tissue of the brain.”
According to him, the devices have passed clinical trial tests successfully and in addition to receiving ISO, two European standards have also been met.
4155/i
